Cholest-5-ene-3,22(S)-diol (30 mg/kg; p.o.; added in diet, treated for 3 weeks) reduces body weight gain and abolishes high-fat diet-induced increase of triacylglycerol (TAG) levels in serum[2].
Pharmacokinetic Analysis in Rats[2]
| Route | Dose (mg/kg) | Cmax (ng/mL) | Tmax (h) | AUCt (ng·h/mL) | AUC (ng·h/mL) | T1/2 (h) | Extent of tritium exchange (%) |
| i.v. | 50 | 22.4 | 0.08 | 174 | 195 | 8.1 | 2.8 |
| p.o. | 50 | 7.5 | 4 | 95.2 | 104 | 6.4 | 1.2 |
| Animal Model: | Male rats injected with Pentobarbital (20 mg, 50 mg/mL; i.p.)[2] |
| Dosage: | 30 mg/kg/day |
| Administration: | Oral gavage; 3 weeks consecutively |
| Result: | Decreased body weight gain significantly after 1 week treatment.
Increased gene expression of Ucp3 and Cpt2 in liver and skeletal muscle, and increased protein level of Ucp3 in skeletal muscle after 3 weeks treatment. |
